RecruitingPhase 1NCT03911388
Rare condition
Ependymoma
29
studies recruiting now
as of 7 Sept 2026
321
studies registered in total
as of 7 Sept 2026
1
countries with a recruiting site
as of 7 Sept 2026
24 Jun 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1NCT07390539
B7-H3.CD28Z.CART in CNS Neoplasms
RecruitingPhase 1NCT07664176
NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors
RecruitingPhase 2NCT04374305
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
RecruitingNCT00598351
Natural History Study of Patients With Neurofibromatosis Type 2
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 29 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Ependymoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Ependymoma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (ZFTA).
Treatments being studied
1 approved treatment and 10 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Carmustine (Bicnu)
Phase 2Marizomib
Phase 2Dextrose (Capd)
Phase 2Carboplatin (Carboplatin)
Phase 2Erlotinib
Phase 2Methionine
Phase 2Antineoplaston A10
Phase 1Imiquimod (Aldara)
Phase 1Azacitidine (Azacitidine)
+ 2 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).